News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Release: Immune Responses Enhanced And Sustained When PROVENGE® (Sipuleucel-T) Is Given After Androgen Deprivation Therapy In Biochemically-Recurrent Prostate Cancer


4/11/2014 8:15:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--April 11, 2014 – Dendreon Corporation (NASDAQ:DNDN) today announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE® (sipuleucel-T) is given after androgen deprivation therapy (ADT) in patients with biochemically-recurrent prostate cancer (BRPC) at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology (EAU) Congress taking place from April 11-15, 2014 in Stockholm, Sweden.1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES